OneSource Specialty Pharma Limited announced its unaudited consolidated and standalone financial results for the quarter and six months ended September 30, 2025. The Board of Directors approved the results on November 11, 2025. Consolidated revenue from operations reached ₹3,757.63 million for the quarter. Basic EPS stands at ₹0.92. The composite scheme is pending regulatory approval.
Financial Performance Overview
OneSource Specialty Pharma Limited has released its unaudited financial results for Q2 2025. Key highlights from the consolidated results include:
- Revenue from Operations: ₹3,757.63 million
- Total Income: ₹3,787.99 million
Key Financial Metrics
The consolidated financial results reveal the following key metrics:
- Profit/Loss before tax: ₹57.41 million
- Profit/Loss after tax: ₹104.85 million
- Basic EPS: ₹0.92
Segment Performance
The company’s revenue is derived primarily from CDMO (Contract Development and Manufacturing Organization) activities.
- CDMO Revenue: ₹3,757.63 million for Q2 2025
Additional Points
A composite scheme is currently awaiting necessary regulatory approvals. The results are based on Indian Accounting Standards (Ind AS).
Standalone Performance
Key highlights from the standalone results include:
- Total Income: ₹3,782.23 million
- Profit before tax: ₹371.01 million
- Profit after tax: ₹371.01 million
Source: BSE
